Home > Insider Trading > Biontech Se > Profile

Biontech Se (BNTX)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Hedge Fund Popularity

Display

13F filing is ongoing

Display Share Price

Display Large Version

Hedge Fund Holdings

Filing Period:

Last updated on June 18, 2025, 3:30 pm based on SEC 13F filings Last update: June 18, 2025, 3:30 pm

No.	Hedge Fund	Shares	Value	Activity	% Port
1.	Viking Global Andreas Halvorsen	879,972	$80,130,250	-7%	0.25%
2.	Millennium Management Israel Englander	544,970	$49,624,968	+219%	0.03%
3.	Citadel Investment GroupCALL Ken Griffin	374,400	$34,092,864	-8%	0.01%
4.	Squarepoint Ops LLC Maxime Fortin (Cio)	347,727	$31,664,021	-6%	0.04%
5.	Tang Capital Management Kevin C. Tang	270,000	$24,586,200		1.36%

Institutional Investors' Holdings

Filing Period: Filing is Ongoing

No.	Name	Shares	Value	% Port
1.	Garde Capital, Inc.	50	$5,324	0%

News See All

Truist Lifts BioNTech (BNTX) Price Target After New Partnership

This decision came after the company entered into an agreement with Bristol Myers Squibb for the co-development and co-commercialization of BioNTech SE’s (NASDAQ:BNTX) investigational bispecific antibody...

Keep Reading →

June 3rd, 2025 - News

Why BioNTech SE (BNTX) Skyrocketed On Monday

We recently published a list of These 10 Stocks Blew Past Expectations.

Keep Reading →

June 3rd, 2025 - News

Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the global biopharmaceutical market.

Keep Reading →

June 2nd, 2025 - News

Bristol-Myers (BMY) Licenses BioNTech's Immunotherapy in $11 billion Deal

On Monday, June 2, Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing agreement focused on next-generation oncology therapies...

Keep Reading →

June 2nd, 2025 - News

BioNTech Strengthens UK Ties with Investment of Up to $1.33 Billion

German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an investment of up to £1 billion ($1.33 billion) over the next decade, focusing...

Keep Reading →

May 21st, 2025 - News